Page last updated: 2024-11-07

aldosterone and Cardiac Hypertrophy

aldosterone has been researched along with Cardiac Hypertrophy in 139 studies

Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.

Research Excerpts

ExcerptRelevanceReference
"The effects of sacubitril/valsartan (S/V) on the renin-angiotensin-aldosterone system (RAAS) in dogs with cardiomegaly secondary to myxomatous mitral valve disease (MMVD) are currently unknown."9.27A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease. ( Duran, SH; Jung, S; Newhard, DK; Winter, RL, 2018)
"The effects of a sustained-release formulation of the calcium antagonist nicardipine on left ventricular (LV) mass, Doppler transmitral velocity profiles and plasma neurohumoral studies were analyzed in patients with mild to moderate systemic hypertension."9.07Effects of sustained-release nicardipine on regression of left ventricular hypertrophy in systemic hypertension. ( Adler, J; Dittrich, HC; Ong, J; Reitman, M; Weber, M; Ziegler, M, 1992)
" We evaluated the effects of aldosterone antagonist spironolactone on cardiac remodeling in rats with ascending aortic stenosis (AS)."7.83Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload. ( Campos, DHS; Cezar, MDM; Cicogna, AC; Costa, LCO; Damatto, RL; Iyomasa, RM; Martinez, PF; Minicucci, MF; Okoshi, K; Okoshi, MP; Silva, MB, 2016)
"To investigate the in vivo and in vitro protective effects of pentamethylquercetin (PMQ), a member of polymethoxy flavonoids (PMFs), on cardiac hypertrophy."7.78In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy. ( Chen, L; Chen, Y; Han, Y; He, T; Jin, MW; Yang, WQ, 2012)
"Persistent β-adrenergic receptor stimulation with isoproterenol is associated with cardiac hypertrophy as well as cardiac synthesis of angiotensin II."7.78Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. ( Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012)
"The aim of this paper is to report a case of unilateral PA with spontaneous remission and reduction of cardiac hypertrophy after long-term spironolactone (SP) therapy."7.78Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy. ( Demura, M; Karashima, S; Kometani, M; Takata, H; Takeda, Y; Yamagishi, M; Yoneda, T, 2012)
"Eplerenone, a selective aldosterone blocker, has been shown to attenuate cardiac fibrosis and decrease cardiovascular events in both experimental and clinical studies."7.73Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. ( Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A, 2006)
" This increase is mediated primarily by cardiac angiotensin II via AT1-subtype receptor and may be involved in post-MI ventricular fibrosis and in control of tissue norepinephrine concentration."7.70Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. ( Aupetit-Faisant, B; Carayon, A; Delcayre, C; Heymes, C; Oubénaïssa, A; Robert, V; Silvestre, JS; Swynghedauw, B, 1999)
"The effect of manidipine on cardiac hypertrophy, coronary circulation, left ventricular weight and maximal coronary flow in hypertension was measured in DOCA/salt treated systolic hypertensive rats with and without manidipine treatment."7.68Effect of manidipine on cardiac hypertrophy and coronary circulation in DOCA/salt hypertensive rats. ( Asayama, J; Itoh, H; Kuwabara, T; Nakagawa, M; Nakata, T; Sasaki, S; Takeda, K; Takesako, T; Tanabe, S; Yamahara, Y, 1992)
"To assess the role of dietary sodium in the regional development and pathogenesis of isoproterenol (ISO)-induced cardiac hypertrophy, male Fischer rats (150-175g n = 65) were divided into control (C) and ISO-treated (I) and three dietary sodium subgroups; low (8."7.68Alterations in dietary sodium affect isoproterenol-induced cardiac hypertrophy. ( Allard, MF; Bishop, SP; DeVenny, MF; Doss, LK; Grizzle, WE, 1990)
"To study the effects of a novel angiotensin I converting enzyme inhibitor (ACEI) on hypertension-induced cardiac hypertrophy, benazepril hydrochloride (CGS 14824 A, CAS 86541-74-4) at the dose of 3 and 10 mg/kg/d p."7.68Effect of benazepril hydrochloride on cardiac hypertrophy in spontaneously hypertensive rats. ( Hasegawa, Y; Inukai, T; Katahira, J; Nakao, K; Takemori, E, 1991)
"To study the effects of Ca antagonists on hypertension induced cardiac and vascular hypertrophy, diltiazem, at the doses of 30 and 60 mg/kg, p."7.67[Effects of diltiazem on developing blood pressure and accompanying cardiac and vascular hypertrophy in SHR]. ( Inamasu, M; Iwasaki, HO; Morita, T; Nagao, T; Narita, H, 1985)
"Heart failure is a major cause of cardiovascular morbidity and mortality and its incidence is on the increase."6.43Neurohormones and heart failure: the importance of aldosterone. ( Ferro, A; Odedra, K, 2006)
"In untreated congestive heart failure, aldosterone plasma concentrations are elevated in proportion to the severity of the disease and are further increased by the use of diuretic treatment."6.39Aldosterone and heart failure. ( Zannad, F, 1995)
"Thus, BST-1 may exacerbate cardiac hypertrophy by activating the Ca2+/CaN/NFATc3 pathway."5.91BST-1 aggravates aldosterone-induced cardiac hypertrophy via the Ca2+ /CaN/NFATc3 pathway. ( Cao, H; Fu, L; Huang, F; Li, A; Li, S; Liao, C; Wang, X; Yuan, Y; Zeng, W; Zhang, B; Zhao, L, 2023)
"Telmisartan was administered to renovascular hypertensive rats at either a high dose (5 mg per kg per day; high-T group) or a low dose (0."5.35Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats. ( Hongo, K; Kawai, M; Komukai, K; Mochizuki, S; Morimoto, S; Nagai, M; Seki, S; Taniguchi, I; Yoshimura, M, 2009)
"Uremia was associated to myocardial hypertrophy, fibrosis and apoptosis."5.33Effect of parathyroidectomy on cardiac fibrosis and apoptosis: possible role of aldosterone. ( Amato, D; Avila-Díaz, M; Foyo-Niembro, E; Paniagua, R; Ramirez-San-Juan, E; Rodríguez-Ayala, E, 2006)
"However, tempol failed to suppress cardiac hypertrophy, the formation of inflammatory lesions, and upregulation of cardiac MCP-1 and osteopontin by aldosterone, while N-acetylcysteine could inhibit all of them."5.33Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. ( Iwao, H; Izumi, Y; Izumiya, Y; Kim-Mitsuyama, S; Ueda, M; Wake, R; Yoshida, K; Yoshiyama, M; Yukimura, T, 2005)
"1."5.32Endothelin ETA receptor antagonism does not attenuate angiotensin II-induced cardiac hypertrophy in vivo in rats. ( De Smet, HR; Menadue, MF; Oliver, JR; Phillips, PA, 2003)
"Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure."5.32Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003)
"High sodium intake causes cardiac hypertrophy independently of increases in blood pressure."5.31Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. ( Demura, M; Mabuchi, H; Miyamori, I; Takeda, Y; Yoneda, T, 2000)
"A case of primary hyperaldosteronism and cardiomegaly due to a unilateral adrenal adenoma in a newborn is presented."5.30Hypertensive cardiomegaly caused by an aldosterone-secreting adenoma in a newborn. ( Armanini, D; Cecchetto, G; Fassina, A; Opocher, G; Pozzan, GB; Rigon, F; Zacchello, F, 1997)
"The effects of sacubitril/valsartan (S/V) on the renin-angiotensin-aldosterone system (RAAS) in dogs with cardiomegaly secondary to myxomatous mitral valve disease (MMVD) are currently unknown."5.27A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease. ( Duran, SH; Jung, S; Newhard, DK; Winter, RL, 2018)
"The effects of a sustained-release formulation of the calcium antagonist nicardipine on left ventricular (LV) mass, Doppler transmitral velocity profiles and plasma neurohumoral studies were analyzed in patients with mild to moderate systemic hypertension."5.07Effects of sustained-release nicardipine on regression of left ventricular hypertrophy in systemic hypertension. ( Adler, J; Dittrich, HC; Ong, J; Reitman, M; Weber, M; Ziegler, M, 1992)
"In a double-blind 6 month trial, the cardiac effects of captopril and minoxidil, administered as third step treatments, were compared in 34 men with essential hypertension and diastolic blood pressure greater than 95 mm Hg who were taking 200 mg/day of metoprolol and 80 mg/day of furosemide."5.06Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: a 6 month double-blind comparison. ( Chatellier, G; Corvol, P; Dufloux, MA; Julien, J; Menard, D; Menard, J; Plouin, PF; Prasquier, R, 1990)
" The 30% improvement in mortality (and 35% in morbidity) seen in the RALES trial with the addition of low-dose spironolactone to best practice therapy in moderate to severe heart failure, similarly points to an unrecognized role for aldosterone in the pathophysiology of heart failure."4.81Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system. ( Funder, JW; Young, MJ, 2002)
" We evaluated the effects of aldosterone antagonist spironolactone on cardiac remodeling in rats with ascending aortic stenosis (AS)."3.83Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload. ( Campos, DHS; Cezar, MDM; Cicogna, AC; Costa, LCO; Damatto, RL; Iyomasa, RM; Martinez, PF; Minicucci, MF; Okoshi, K; Okoshi, MP; Silva, MB, 2016)
"Persistent β-adrenergic receptor stimulation with isoproterenol is associated with cardiac hypertrophy as well as cardiac synthesis of angiotensin II."3.78Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. ( Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012)
"The aim of this paper is to report a case of unilateral PA with spontaneous remission and reduction of cardiac hypertrophy after long-term spironolactone (SP) therapy."3.78Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy. ( Demura, M; Karashima, S; Kometani, M; Takata, H; Takeda, Y; Yamagishi, M; Yoneda, T, 2012)
" We analysed the effects of early chronic VPI (50 mg/kg/day Omapatrilat) on cardiac remodelling and neurohumoral function during the progression of rapid ventricular pacing-induced heart failure in rabbits (early left ventricular dysfunction [ELVD]: 10 days at 330 bpm, CHF: further 10 days at 360 bpm)."3.78Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure. ( Birner, C; Bratfisch, M; Dietl, A; Götz, T; Luchner, A; Riegger, GA; Schweda, F; Ulucan, C, 2012)
"To investigate the in vivo and in vitro protective effects of pentamethylquercetin (PMQ), a member of polymethoxy flavonoids (PMFs), on cardiac hypertrophy."3.78In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy. ( Chen, L; Chen, Y; Han, Y; He, T; Jin, MW; Yang, WQ, 2012)
"We evaluated 2119 Framingham Offspring Study participants (mean age, 57 years; 57% women) who underwent measurements of biomarkers of inflammation (C-reactive protein), hemostasis (fibrinogen and plasminogen activator inhibitor-1), neurohormonal activation (B-type natriuretic peptide), and renin-angiotensin-aldosterone system (aldosterone and renin modeled as a ratio [ARR]) and echocardiography at a routine examination."3.74Relations of biomarkers representing distinct biological pathways to left ventricular geometry. ( Aragam, J; Benjamin, EJ; Gona, P; Larson, MG; Levy, D; Lieb, W; Tofler, GH; Vasan, RS; Velagaleti, RS; Wang, TJ, 2008)
" We investigated its role in angiotensin II-induced hypertension in the Tsukuba hypertensive mouse (THM)."3.74Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse. ( Bak, S; Coleman, T; Osher, E; Semenkovich, CF; Stern, N; Tordjman, KM; Vechoropoulos, M; Yudovich, R, 2007)
"Eplerenone, a selective aldosterone blocker, has been shown to attenuate cardiac fibrosis and decrease cardiovascular events in both experimental and clinical studies."3.73Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats. ( Abe, Y; Izumi, T; Mochizuki, S; Taniguchi, I; Urabe, A, 2006)
" The effect of the angiotensin II type 1 receptor antagonist, losartan (10 mg x kg(-1) x d(-1))on aldosterone-induced cardiac hypertrophy was also studied."3.71Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. ( Demura, M; Mabuchi, H; Takeda, Y; Usukura, M; Yoneda, T, 2002)
" This increase is mediated primarily by cardiac angiotensin II via AT1-subtype receptor and may be involved in post-MI ventricular fibrosis and in control of tissue norepinephrine concentration."3.70Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. ( Aupetit-Faisant, B; Carayon, A; Delcayre, C; Heymes, C; Oubénaïssa, A; Robert, V; Silvestre, JS; Swynghedauw, B, 1999)
" Even though the angiotensin converting enzyme inhibitor captopril was previously found to attenuate this interstitial and perivascular fibrosis, the relative importance of arterial and ventricular systolic pressures versus circulating angiotensin II (AII) and aldosterone (AL) in promoting hypertrophy and collagen accumulation in renovascular hypertension is uncertain."3.68Remodeling of the rat right and left ventricles in experimental hypertension. ( Brilla, CG; Janicki, JS; Pick, R; Tan, LB; Weber, KT, 1990)
"To study the effects of a novel angiotensin I converting enzyme inhibitor (ACEI) on hypertension-induced cardiac hypertrophy, benazepril hydrochloride (CGS 14824 A, CAS 86541-74-4) at the dose of 3 and 10 mg/kg/d p."3.68Effect of benazepril hydrochloride on cardiac hypertrophy in spontaneously hypertensive rats. ( Hasegawa, Y; Inukai, T; Katahira, J; Nakao, K; Takemori, E, 1991)
"To assess the role of dietary sodium in the regional development and pathogenesis of isoproterenol (ISO)-induced cardiac hypertrophy, male Fischer rats (150-175g n = 65) were divided into control (C) and ISO-treated (I) and three dietary sodium subgroups; low (8."3.68Alterations in dietary sodium affect isoproterenol-induced cardiac hypertrophy. ( Allard, MF; Bishop, SP; DeVenny, MF; Doss, LK; Grizzle, WE, 1990)
"The effect of manidipine on cardiac hypertrophy, coronary circulation, left ventricular weight and maximal coronary flow in hypertension was measured in DOCA/salt treated systolic hypertensive rats with and without manidipine treatment."3.68Effect of manidipine on cardiac hypertrophy and coronary circulation in DOCA/salt hypertensive rats. ( Asayama, J; Itoh, H; Kuwabara, T; Nakagawa, M; Nakata, T; Sasaki, S; Takeda, K; Takesako, T; Tanabe, S; Yamahara, Y, 1992)
"To study the effects of Ca antagonists on hypertension induced cardiac and vascular hypertrophy, diltiazem, at the doses of 30 and 60 mg/kg, p."3.67[Effects of diltiazem on developing blood pressure and accompanying cardiac and vascular hypertrophy in SHR]. ( Inamasu, M; Iwasaki, HO; Morita, T; Nagao, T; Narita, H, 1985)
"Primary aldosteronism is the most common cause of mineralocorticoid-induced hypertension, and MR antagonism offers the best prospect for achieving therapeutic goals."2.44Mineralocorticoid antagonism and cardiac hypertrophy. ( Nagata, K, 2008)
"Heart failure is a major cause of cardiovascular morbidity and mortality and its incidence is on the increase."2.43Neurohormones and heart failure: the importance of aldosterone. ( Ferro, A; Odedra, K, 2006)
"Aldosterone has several deleterious properties."2.41Aldosterone: cardiovascular assault. ( Struthers, AD, 2002)
"In untreated congestive heart failure, aldosterone plasma concentrations are elevated in proportion to the severity of the disease and are further increased by the use of diuretic treatment."2.39Aldosterone and heart failure. ( Zannad, F, 1995)
"Cyclovirobuxine D (CVB-D) is a natural alkaloid that exhibits multiple pharmacological activities, such as anti-inflammatory, anti-oxidative stress, and anti-cancer properties."1.91Cyclovirobuxine D alleviates aldosterone-induced myocardial hypertrophy by protecting mitochondrial function depending on the mutual regulation of Nrf2-SIRT3. ( An, J; Chen, Y; Fu, L; Liang, G; Shen, X; Tao, L; Wang, X; Wu, H; Zhang, G, 2023)
"Thus, BST-1 may exacerbate cardiac hypertrophy by activating the Ca2+/CaN/NFATc3 pathway."1.91BST-1 aggravates aldosterone-induced cardiac hypertrophy via the Ca2+ /CaN/NFATc3 pathway. ( Cao, H; Fu, L; Huang, F; Li, A; Li, S; Liao, C; Wang, X; Yuan, Y; Zeng, W; Zhang, B; Zhao, L, 2023)
"It showed that cardiac hypertrophy was associated with obesity while microalbuminuria was related to plasma aldosterone concentration (PAC) in PA patients."1.72Clinical Characteristics of Target Organ Damage in Primary Aldosteronism with or without Metabolic Syndrome. ( Bu, X; He, H; Li, Y; Liu, X; Sun, F; Yan, Z; Zhang, H; Zhao, Z; Zhu, Z, 2022)
"Primary aldosteronism is characterized by excess aldosterone secretion by the adrenal gland independent of the renin-angiotensin system and accounts for ~10% of hypertensive patients."1.48MicroRNA-21 ablation exacerbates aldosterone-mediated cardiac injury, remodeling, and dysfunction. ( Ball, JP; Hall, ME; Mathis, KW; Romero, DG; Rothenberg, ME; Ryan, MJ; Syed, M; Yanes Cardozo, LL, 2018)
"Furthermore, cardiac hypertrophy and sclerosis of the arteries of various organs had progressed, suggesting an influence of persistent endocrinal hypertension."1.39An autopsy case of bilateral adrenal pheochromocytoma-associated cerebral hemorrhage. ( Fukunaga, T; Hara, S; Kobayashi, M; Kuriiwa, F; Mizukami, H; Mori, S, 2013)
"Arterial hypertension (AH) induces cardiac hypertrophy and reactivation of "fetal" gene expression."1.38Aldosterone inhibits the fetal program and increases hypertrophy in the heart of hypertensive mice. ( Azibani, F; Carrier, L; Chatziantoniou, C; Coutance, G; Delcayre, C; Devaux, Y; Fazal, L; Launay, JM; Merval, R; Polidano, E; Samuel, JL; Schlossarek, S; Solal, AC, 2012)
"To prevent cardiac hypertrophy and heart failure, it is necessary to identify and characterize molecules that may regulate the hypertrophic program."1.36miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. ( Li, PF; Long, B; Wang, K; Zhou, J, 2010)
"Despite displaying cardiac hypertrophy at baseline and higher blood pressure responses to L-NAME/AngII, cav-1 KO mice displayed, as compared with WT, decreased treatment-induced biventricular damage as well as decreased transcript levels of the proinflammatory marker plasminogen activator inhibitor-1."1.36Caveolin-1 ablation reduces the adverse cardiovascular effects of N-omega-nitro-L-arginine methyl ester and angiotensin II. ( Adler, GK; Coutinho, P; Guo, C; Lapointe, N; Loutraris, P; Pojoga, LH; Ricchiuti, V; Romero, JR; Stone, JR; Williams, GH; Yao, TM, 2010)
"Aldosterone (ALDO) may induce cardiac hypertrophy by nonhemodynamic mechanisms that are not completely defined."1.35Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes. ( Díez, J; Fortuño, MA; Gallego, I; Iñigo, C; López-Andrés, N, 2008)
"Telmisartan was administered to renovascular hypertensive rats at either a high dose (5 mg per kg per day; high-T group) or a low dose (0."1.35Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats. ( Hongo, K; Kawai, M; Komukai, K; Mochizuki, S; Morimoto, S; Nagai, M; Seki, S; Taniguchi, I; Yoshimura, M, 2009)
"Cardiac hypertrophy is accompanied by maladaptive cardiac remodeling, which leads to heart failure or sudden death."1.35miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. ( Gao, J; Jiao, J; Li, PF; Lin, Z; Murtaza, I; Wang, K, 2009)
"Uremia was associated to myocardial hypertrophy, fibrosis and apoptosis."1.33Effect of parathyroidectomy on cardiac fibrosis and apoptosis: possible role of aldosterone. ( Amato, D; Avila-Díaz, M; Foyo-Niembro, E; Paniagua, R; Ramirez-San-Juan, E; Rodríguez-Ayala, E, 2006)
"However, tempol failed to suppress cardiac hypertrophy, the formation of inflammatory lesions, and upregulation of cardiac MCP-1 and osteopontin by aldosterone, while N-acetylcysteine could inhibit all of them."1.33Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. ( Iwao, H; Izumi, Y; Izumiya, Y; Kim-Mitsuyama, S; Ueda, M; Wake, R; Yoshida, K; Yoshiyama, M; Yukimura, T, 2005)
"The GK rats developed hypertension, cardiac hypertrophy and overexpression of cardiac natriuretic peptides and profibrotic connective tissue growth factor compared to nondiabetic Wistar rats."1.33Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats. ( Bäcklund, T; Cheng, ZJ; Eriksson, A; Finckenberg, P; Grönholm, T; Laine, M; Mervaala, E; Palojoki, E; Tikkanen, I; Vuolteenaho, O, 2005)
" To address this issue and taking into account that effects of synthetic progestins are not only referable to action through the progesterone receptor but may also be mediated by other steroid receptors, we characterized cardiovascular function and inflammatory gene expression in aldosterone salt-treated rats on long-term administration of 17beta-estradiol, medroxyprogesterone acetate, and drospirenone, a new progestogen exhibiting antimineralocorticoid activity."1.33Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats. ( Arias-Loza, PA; Bauersachs, J; Ertl, G; Fritzemeier, KH; Galle, J; Hegele-Hartung, C; Hu, K; Jazbutyte, V; Neyses, L; Pelzer, T; Quaschning, T; Schäfer, A, 2006)
"Aldosterone classically promotes unidirectional transepithelial sodium transport, thereby regulating blood volume and blood pressure."1.32Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. ( Blomme, EA; Bond, BR; Funder, JW; Goellner, JJ; McMahon, EG; Qin, W; Rocha, R; Rudolph, AE, 2003)
"These results demonstrate that residual aldosterone has a significant impact on target-organ damage in hypertension, even during chronic administration of an ARB."1.32Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats. ( Hara, Y; Imaki, T; Naruse, M; Nishikawa, T; Sato, A; Takano, K; Tanabe, A; Tsuchiya, K, 2004)
"1."1.32Endothelin ETA receptor antagonism does not attenuate angiotensin II-induced cardiac hypertrophy in vivo in rats. ( De Smet, HR; Menadue, MF; Oliver, JR; Phillips, PA, 2003)
"Spironolactone prevented cardiac hypertrophy in adrenalectomized SHRSP."1.31Cardiac aldosterone production in genetically hypertensive rats. ( Demura, M; Mabuchi, H; Miyamori, I; Takeda, Y; Yoneda, T, 2000)
" Losartan improved the shifted circadian BP rhythm towards the active phase in a dose-dependent manner, whereas the improvement caused by 1 and 3 mg/day of benazepril was less effective than the same dosage of losartan."1.31Effects of losartan and benazepril on abnormal circadian blood pressure rhythm and target organ damage in SHRSP. ( Hayasaki-Kajiwara, Y; Iwasaki, T; Nakajima, M; Naya, N; Shimamura, T, 2002)
"High sodium intake causes cardiac hypertrophy independently of increases in blood pressure."1.31Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. ( Demura, M; Mabuchi, H; Miyamori, I; Takeda, Y; Yoneda, T, 2000)
"L-NAME treatment induced hypertension that was associated with increased plasma renin activity."1.30Vascular smooth muscle cell polyploidy and cardiomyocyte hypertrophy due to chronic NOS inhibition in vivo. ( Brosnan, MJ; Devlin, AM; Dominiczak, AF; Graham, D; Hamilton, CA; McIntyre, M; McPhaden, AR; Morton, JJ; Reid, JL, 1998)
"A case of primary hyperaldosteronism and cardiomegaly due to a unilateral adrenal adenoma in a newborn is presented."1.30Hypertensive cardiomegaly caused by an aldosterone-secreting adenoma in a newborn. ( Armanini, D; Cecchetto, G; Fassina, A; Opocher, G; Pozzan, GB; Rigon, F; Zacchello, F, 1997)
" Co-administration with propranolol markedly decreased the heart rate, but little affected the heart weight, suggesting changes in the heart rate during the long-term administration of KW-3049 did not largely affect cardiac hypertrophy."1.29Effect of the new calcium antagonist (+/-)-(R*)-3-[(R*)-1-benzyl-3- piperidyl] methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5- pyridinedicarboxylate hydrochloride (KW-3049) on cardiac hypertrophy in spontaneously hypertensive rats. ( Deguchi, T; Hara, T; Hattori, O; Kato, Y; Saijyo, T; Suzuki, K; Tanaka, H, 1993)
" Therefore, after 4 weeks of washout with placebo (phase 1), doxazosin (dosage range from 1 to 16 mg, plus hydrochlorothiazide when necessary) was given to 11 essential hypertensive patients (6 M, 5 F, age range 34-63 years) for 8 weeks (phase 2) in order to achieve diastolic blood pressure values less than 90 mmHg; this dosage was then maintained for a further 20 weeks up to the end of the study (phase 3)."1.28Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin. ( Agabiti-Rosei, E; Beschi, M; Calebich, S; Castellano, M; Muiesan, G; Muiesan, ML; Rizzoni, D; Zulli, R, 1992)
"Hence, cardiac hypertrophy during chronic exposure to cold is supported by other factors, possibly by the increased concentration of either norepinephrine or triiodothyronine, or both, which occurs characteristically in rats under these conditions."1.28Effect of a reduction in sodium intake on cold-induced elevation of blood pressure in the rat. ( Fregly, MJ; Papanek, PE; van Bergen, P, 1992)
"Spironolactone was able largely to prevent the perivascular/interstitial fibrosis and scarring in either model irrespective of the development of left ventricular hypertrophy and arterial hypertension."1.28Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. ( Brilla, CG; Weber, KT, 1992)
" Thus, in the presence of enhanced sodium intake, chronic administration of ALDO or DOCA are associated with collagen accumulation in the myocardium, whereas with the mineralocorticoid-like compound GA, myocardial fibrosis was not seen."1.28Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. ( Brilla, CG; Weber, KT, 1992)
"Aldosterone excretion was in HL with EH substantially lower, and sodium excretion higher, than in a comparable group of lowland inhabitants."1.27Prevalence and clinical peculiarities of essential hypertension in a population living at high altitude. ( Dzhumagulova, AS; Meimanaliev, TS; Mirrakhimov, MM; Murataliev, TM; Rafibekova, ZhS; Shatemirova, KK, 1985)
"Patients with primary aldosteronism and unilateral renovascular hypertension of similar blood pressure levels, age and sex have almost identical degrees of left ventricular hypertrophy and anatomy."1.27Left ventricular structural characteristics in unilateral renovascular hypertension and primary aldosteronism. ( Abe, H; Ashizawa, A; Iwata, S; Kuramochi, M; Nagata, S; Omae, T; Saitoh, F; Suzuki, T, 1988)
"A case of an adult with Bartter's syndrome (hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis) is described; the patient had the unusual manifestation of cardiomyopathy, probably secondary to severe hypokalemia."1.26Cardiomyopathy in an adult with Bartter's syndrome and hypokalemia. Hemodynamic, angiographic and metabolic studies. ( Dalakos, TG; Jones, D; Potts, JL; Streeten, DH, 1977)

Research

Studies (139)

TimeframeStudies, this research(%)All Research%
pre-199019 (13.67)18.7374
1990's28 (20.14)18.2507
2000's49 (35.25)29.6817
2010's38 (27.34)24.3611
2020's5 (3.60)2.80

Authors

AuthorsStudies
Bu, X1
Sun, F1
Zhang, H1
Liu, X1
Zhao, Z1
He, H1
Li, Y1
Yan, Z1
Zhu, Z1
Yuan, Y1
Zhao, L1
Cao, H1
Li, S4
Liao, C1
Fu, L2
Wang, X3
Huang, F1
Zeng, W1
Li, A1
Zhang, B1
Kmieć, P1
Rosenkranz, S1
Odenthal, M1
Caglayan, E1
Wu, H1
An, J1
Zhang, G1
Chen, Y2
Tao, L1
Liang, G1
Shen, X1
Cao, W1
Wang, B1
Zhan, E1
Xu, J2
Slavic, S1
Ford, K1
Modert, M1
Becirovic, A1
Handschuh, S1
Baierl, A1
Katica, N1
Zeitz, U1
Erben, RG1
Andrukhova, O1
Chou, CH1
Hung, CS1
Liao, CW1
Wei, LH1
Chen, CW1
Shun, CT1
Wen, WF1
Wan, CH1
Wu, XM1
Chang, YY1
Wu, VC1
Wu, KD1
Lin, YH1
de Paula Vasconcelos, PC1
Tirloni, CAS1
Palozi, RAC1
Leitão, MM1
Carneiro, MTS1
Schaedler, MI1
Silva, AO1
Souza, RIC1
Salvador, MJ1
Junior, AG1
Kassuya, CAL1
Newhard, DK1
Jung, S1
Winter, RL1
Duran, SH1
Syed, M1
Ball, JP1
Mathis, KW1
Hall, ME1
Ryan, MJ1
Rothenberg, ME1
Yanes Cardozo, LL1
Romero, DG1
Araos, P1
Prado, C1
Lozano, M1
Figueroa, S1
Espinoza, A1
Berger, T1
Mak, TW1
Jaisser, F1
Pacheco, R1
Michea, L1
Amador, CA1
Duda, T1
Pertzev, A1
Sharma, RK1
Yasuoka, S1
Kai, H1
Kajimoto, H1
Kudo, H1
Takayama, N1
Anegawa, T1
Koga, M1
Miyamoto, T1
Mifune, H1
Kage, M1
Hirooka, Y1
Imaizumi, T1
Masutani, S1
Saiki, H1
Kurishima, C1
Ishido, H1
Tamura, M1
Senzaki, H1
Gómez, AM1
Ruiz-Hurtado, G1
Benitah, JP1
Domínguez-Rodríguez, A1
Katayama, IA2
Pereira, RC1
Dopona, EP1
Shimizu, MH1
Furukawa, LN2
Oliveira, IB2
Heimann, JC2
Martín-Fernández, B2
Valero Muñoz, M1
de las Heras, N2
Ballesteros, S2
Lahera, V2
Park, BM1
Gao, S1
Cha, SA1
Kim, SH1
Bernhardt, R1
Sakamuri, SS1
Valente, AJ2
Siddesha, JM1
Delafontaine, P1
Siebenlist, U2
Gardner, JD1
Bysani, C1
Mummidi, S1
Das, NA1
Carpenter, AJ1
Kandikattu, H1
Krenz, M1
Chandrasekar, B1
Okoshi, MP1
Cezar, MDM1
Iyomasa, RM1
Silva, MB1
Costa, LCO1
Martinez, PF1
Campos, DHS1
Damatto, RL1
Minicucci, MF1
Cicogna, AC1
Okoshi, K1
Furuzono, S1
Meguro, M1
Miyauchi, S1
Inoue, S1
Homma, T1
Yamada, K1
Tagawa, YI1
Nara, F1
Nagayama, T1
López-Andrés, N1
Iñigo, C1
Gallego, I1
Díez, J1
Fortuño, MA1
Nagata, K2
Velagaleti, RS1
Gona, P1
Levy, D1
Aragam, J1
Larson, MG1
Tofler, GH1
Lieb, W1
Wang, TJ1
Benjamin, EJ1
Vasan, RS1
Aplin, M1
Christensen, GL1
Hansen, JL1
Kawai, M1
Hongo, K1
Komukai, K1
Morimoto, S1
Nagai, M1
Seki, S1
Taniguchi, I2
Mochizuki, S2
Yoshimura, M2
Klusonová, P1
Reháková, L1
Borchert, G1
Vagnerová, K1
Neckár, J1
Ergang, P1
Miksík, I1
Kolár, F1
Pácha, J1
Park, JK1
Theuer, S1
Kirsch, T1
Lindschau, C1
Klinge, U1
Heuser, A1
Plehm, R1
Todiras, M1
Carmeliet, P1
Haller, H1
Luft, FC2
Muller, DN2
Fiebeler, A1
Lin, Z1
Murtaza, I1
Wang, K2
Jiao, J1
Gao, J1
Li, PF2
Peters, J1
Schlüter, T1
Riegel, T1
Peters, BS1
Beineke, A1
Maschke, U1
Hosten, N1
Mullins, JJ1
Rettig, R1
Bibeau, K1
Battista, MC1
Houde, V1
Brochu, M1
Pojoga, LH1
Romero, JR1
Yao, TM1
Loutraris, P1
Ricchiuti, V1
Coutinho, P1
Guo, C1
Lapointe, N1
Stone, JR1
Adler, GK1
Williams, GH1
Long, B1
Zhou, J2
Shi, H1
Ma, C1
Liu, Y2
Hu, Z1
Wu, D1
Wang, BH1
Bertucci, MC1
Ma, JY1
Adrahtas, A1
Cheung, RY1
Krum, H1
Martinez, FA1
Wang, Q1
Maillard, M1
Schibler, U1
Burnier, M1
Gachon, F1
Usher, MG1
Duan, SZ1
Ivaschenko, CY1
Frieler, RA1
Berger, S1
Schütz, G1
Lumeng, CN1
Mortensen, RM1
Ferreira, DN1
Rosa, KT1
Coelho, MS1
Casarini, DE1
Kujal, P1
Chábová, VČ1
Vernerová, Z1
Walkowska, A1
Kompanowska-Jezierska, E1
Sadowski, J1
Vaňourková, Z1
Husková, Z1
Opočenský, M1
Skaroupková, P1
Schejbalová, S1
Kramer, HJ1
Rakušan, D1
Malý, J1
Netuka, I1
Vaněčková, I1
Kopkan, L1
Cervenka, L1
Ferron, L1
Ruchon, Y1
Renaud, JF1
Capuano, V1
Kurdi, M1
Booz, GW1
He, T1
Chen, L1
Han, Y1
Yang, WQ1
Jin, MW1
Miana, M1
Valero-Muñoz, M1
Vassallo, D1
Davel, AP1
Rossoni, LV1
Cachofeiro, V1
Yoneda, T5
Demura, M4
Takata, H2
Kometani, M1
Karashima, S1
Yamagishi, M2
Takeda, Y6
Komatsu, Y1
Kida, N1
Nozaki, N1
Kuwasako, K1
Nagata, S2
Kitamura, K1
Kato, J1
Azibani, F2
Devaux, Y1
Coutance, G1
Schlossarek, S1
Polidano, E1
Fazal, L2
Merval, R1
Carrier, L1
Solal, AC1
Chatziantoniou, C2
Launay, JM1
Samuel, JL2
Delcayre, C3
Birner, C1
Ulucan, C1
Bratfisch, M1
Götz, T1
Dietl, A1
Schweda, F1
Riegger, GA1
Luchner, A1
Mizukami, H1
Hara, S1
Kobayashi, M1
Mori, S1
Kuriiwa, F1
Fukunaga, T1
Mezősi, E1
Bajnok, L1
Tóth, K1
Karram, T1
Hoffman, A1
Abbasi, A1
Abassi, Z1
Oshima, Y1
Fujio, Y1
Funamoto, M1
Negoro, S1
Izumi, M1
Nakaoka, Y1
Hirota, H1
Yamauchi-Takihara, K1
Kawase, I1
Young, MJ3
Funder, JW8
Struthers, AD1
De Smet, HR1
Menadue, MF1
Oliver, JR1
Phillips, PA1
Qin, W1
Rudolph, AE1
Bond, BR1
Rocha, R1
Blomme, EA1
Goellner, JJ1
McMahon, EG2
Sheppard, KE2
KLAUSGRABER, F1
Karmazyn, M1
Liu, Q1
Gan, XT1
Brix, BJ1
Fliegel, L1
Sun, Y1
Zhang, J1
Lu, L1
Bedigian, MP1
Robinson, AD1
Weber, KT5
Tanabe, A1
Naruse, M1
Hara, Y1
Sato, A2
Tsuchiya, K1
Nishikawa, T1
Imaki, T1
Takano, K1
Matsui, Y1
Jia, N1
Okamoto, H1
Kon, S1
Onozuka, H1
Akino, M1
Liu, L1
Morimoto, J1
Rittling, SR1
Denhardt, D1
Kitabatake, A1
Uede, T1
Schlüter, KD1
Wollert, KC1
Neuberger, HR1
Schotten, U1
Verheule, S1
Eijsbouts, S1
Blaauw, Y1
van Hunnik, A1
Allessie, M1
Grönholm, T1
Cheng, ZJ1
Palojoki, E1
Eriksson, A1
Bäcklund, T1
Vuolteenaho, O1
Finckenberg, P1
Laine, M1
Mervaala, E1
Tikkanen, I1
Yoshida, K1
Kim-Mitsuyama, S1
Wake, R1
Izumiya, Y1
Izumi, Y1
Yukimura, T1
Ueda, M1
Yoshiyama, M1
Iwao, H1
Obata, K1
Ichihara, S1
Noda, A1
Kimata, H1
Kato, T1
Izawa, H1
Murohara, T1
Yokota, M1
Lister, K1
Autelitano, DJ1
Jenkins, A1
Hannan, RD1
Rodríguez-Ayala, E1
Avila-Díaz, M1
Foyo-Niembro, E1
Amato, D1
Ramirez-San-Juan, E1
Paniagua, R1
Chappell, MC1
Yamaleyeva, LM1
Westwood, BM1
Odedra, K1
Ferro, A1
Franco, V1
Chen, YF1
Feng, JA1
Li, P1
Wang, D1
Hasan, E1
Oparil, S1
Perry, GJ1
Arias-Loza, PA1
Hu, K1
Schäfer, A1
Bauersachs, J1
Quaschning, T1
Galle, J1
Jazbutyte, V1
Neyses, L1
Ertl, G1
Fritzemeier, KH1
Hegele-Hartung, C1
Pelzer, T1
Urabe, A1
Izumi, T1
Abe, Y1
Zhu, A1
Usukura, M2
Tordjman, KM1
Semenkovich, CF1
Coleman, T1
Yudovich, R1
Bak, S1
Osher, E1
Vechoropoulos, M1
Stern, N1
Kagiyama, S1
Matsumura, K1
Fukuhara, M1
Sakagami, K1
Fujii, K1
Iida, M1
Klanke, B1
Feldt, S1
Cordasic, N1
Hartner, A1
Schmieder, RE2
Hilgers, KF1
Sun, Z1
Bello-Roufai, M1
Hartford, M1
Wikstrand, J1
Wallentin, I1
Ljungman, S1
Berglund, G1
Prys-Roberts, C1
Raman, VK1
Lee, YA1
Lindpaintner, K1
Kato, Y1
Tanaka, H1
Saijyo, T1
Hattori, O1
Suzuki, K1
Hara, T1
Deguchi, T1
Modena, MG1
Masciocco, G1
Mattioli, G1
Pouleur, H1
Zannad, F1
Pozzan, GB1
Armanini, D1
Cecchetto, G1
Opocher, G1
Rigon, F1
Fassina, A1
Zacchello, F1
González Quijada, S1
Luque Otero, M1
Fernández-Cruz, A1
Almería, C1
Bagazgoitia Barrera, J1
Moya Marín, FJ1
Devlin, AM1
Brosnan, MJ1
Graham, D1
Morton, JJ1
McPhaden, AR1
McIntyre, M1
Hamilton, CA1
Reid, JL1
Dominiczak, AF1
Silvestre, JS1
Heymes, C1
Oubénaïssa, A1
Robert, V1
Aupetit-Faisant, B1
Carayon, A1
Swynghedauw, B1
Miyamori, I2
Mabuchi, H3
Farina, NK1
Johnston, CI1
Burrell, LM1
Remme, WJ1
Shimamura, T1
Iwasaki, T1
Hayasaki-Kajiwara, Y1
Naya, N1
Nakajima, M1
Xiu, JC1
Wu, P1
Xu, JP1
Guo, Z1
Lai, W1
Zhang, Y1
Li, J1
Potts, JL1
Dalakos, TG1
Streeten, DH1
Jones, D1
Wilkins, GE1
Scavo, D1
Cugini, P1
Manconi, R1
Serdoz, R1
Takeda, K1
Nakata, T1
Kuwabara, T1
Itoh, H1
Yamahara, Y1
Takesako, T1
Tanabe, S1
Sasaki, S1
Asayama, J1
Nakagawa, M1
Agabiti-Rosei, E2
Muiesan, ML2
Rizzoni, D1
Zulli, R1
Calebich, S1
Beschi, M2
Castellano, M2
Muiesan, G2
van Bergen, P1
Fregly, MJ1
Papanek, PE1
Resnick, LM1
Brilla, CG4
Dittrich, HC1
Adler, J1
Ong, J1
Reitman, M1
Weber, M1
Ziegler, M1
Pick, R1
Tan, LB1
Janicki, JS1
Bauwens, FR1
Duprez, DA1
De Buyzere, ML1
De Backer, TL1
Kaufman, JM2
Van Hoecke, J2
Vermeulen, A2
Clement, DL2
Takemori, E1
Hasegawa, Y1
Katahira, J1
Nakao, K1
Inukai, T1
De la Sierra, A1
Coca, A1
Sobrino, J1
Lluch, MM1
Sánchez, M1
Urbano-Márquez, A1
Duprez, D1
Bauwens, F1
De Buyzere, M1
De Backer, T1
Julien, J1
Dufloux, MA1
Prasquier, R1
Chatellier, G1
Menard, D1
Plouin, PF1
Menard, J1
Corvol, P1
Allard, MF1
DeVenny, MF1
Doss, LK1
Grizzle, WE1
Bishop, SP1
Fernandez, D1
Bolli, P1
Snedden, W1
Vasdev, S1
Fernandez, PG1
Narita, H1
Nagao, T1
Inamasu, M1
Iwasaki, HO1
Morita, T1
Martin, AF1
Paul, RJ1
Suzuki, T1
Abe, H1
Saitoh, F1
Iwata, S1
Ashizawa, A1
Kuramochi, M1
Omae, T1
Messerli, FH1
Garavaglia, GE1
Nunez, B1
MacPhee, AA1
Re, RN1
Pringle, SD1
Macfarlane, PW1
Isles, CG1
Cameron, HL1
Brown, IA1
Lorimer, AR1
Dunn, FG1
Geri, A1
Romanelli, G1
Andersson, U1
Sylvén, C1
Lindvall, K1
Theodorsson, E1
Norée, LO1
Mirrakhimov, MM1
Rafibekova, ZhS1
Dzhumagulova, AS1
Meimanaliev, TS1
Murataliev, TM1
Shatemirova, KK1
Trimarco, B1
Ricciardelli, B1
De Luca, N1
De Simone, A1
Cuocolo, A1
Galva, MD1
Picotti, GB1
Condorelli, M1
Christenson, WB1
Kaufman, JJ1
Gonick, HC1
Brunner, HR1
Laragh, JH1
Baer, L1
Newton, MA1
Goodwin, FT1
Krakoff, LR1
Bard, RH1
Bühler, FR1
Serebrovskaia, IuA1
Kiseleva, ZM1
Speranskaia, NV1
Spivak, GL1
Paleeva, FM1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Salt Sensitive Hypertension and Striatin[NCT03683069]Phase 4400 participants (Actual)Interventional2019-01-15Active, not recruiting
A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981]Phase 4154 participants (Actual)Interventional2014-06-30Active, not recruiting
Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321]100 participants (Anticipated)Observational2014-01-31Active, not recruiting
Addressing HyperteNsion and Diabetes Through Community-Engaged Systems in Puno, Peru (ANDES Study)[NCT05524987]1,068 participants (Anticipated)Interventional2022-11-30Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

21 reviews available for aldosterone and Cardiac Hypertrophy

ArticleYear
Ca(2+) fluxes involvement in gene expression during cardiac hypertrophy.
    Current vascular pharmacology, 2013, Volume: 11, Issue:4

    Topics: Aldosterone; Animals; Calcineurin; Calcium; Calcium Channels, L-Type; Calcium-Calmodulin-Dependent P

2013
Relevance of SGK1 in structural, functional and molecular alterations produced by aldosterone in heart.
    Hormone molecular biology and clinical investigation, 2014, Volume: 18, Issue:2

    Topics: Aldosterone; Animals; Cardiomegaly; Connective Tissue Growth Factor; Endothelium, Vascular; Fibrosis

2014
The potential of targeting CYP11B.
    Expert opinion on therapeutic targets, 2016, Volume: 20, Issue:8

    Topics: Aldosterone; Animals; Cardiomegaly; Cytochrome P-450 CYP11B2; Drug Design; Humans; Hypertension; Imi

2016
Mineralocorticoid antagonism and cardiac hypertrophy.
    Current hypertension reports, 2008, Volume: 10, Issue:3

    Topics: Aldosterone; Antihypertensive Agents; Cardiomegaly; Fibrosis; Humans; Hyperaldosteronism; Hypertensi

2008
Pharmacologic perspectives of functional selectivity by the angiotensin II type 1 receptor.
    Trends in cardiovascular medicine, 2008, Volume: 18, Issue:8

    Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Cardiomegaly; Cardiovascular D

2008
[The heart as an endocrine organ].
    Orvosi hetilap, 2012, Dec-23, Volume: 153, Issue:51

    Topics: Adipocytes; Adipokines; Aldosterone; Biomarkers; Cardiomegaly; Coronary Artery Disease; Cytokines; H

2012
[Aldosterone--classic and non classic effects].
    Harefuah, 2002, Volume: 141, Issue:6

    Topics: Aldosterone; Cardiomegaly; Collagen; Genes, ras; Heart; Humans; Muscle, Skeletal; Sodium Channels

2002
Mineralocorticoid receptors and pathophysiological roles for aldosterone in the cardiovascular system.
    Journal of hypertension, 2002, Volume: 20, Issue:8

    Topics: Aldosterone; Animals; Cardiomegaly; Cardiovascular System; Heart Failure; Humans; Hyperaldosteronism

2002
Aldosterone: cardiovascular assault.
    American heart journal, 2002, Volume: 144, Issue:5 Suppl

    Topics: Aldosterone; Autonomic Nervous System Diseases; Cardiomegaly; Endothelium, Vascular; Fibrinolysis; F

2002
New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone.
    American heart journal, 2002, Volume: 144, Issue:5 Suppl

    Topics: Aldosterone; Animals; Cardiomegaly; Clinical Trials as Topic; Desoxycorticosterone; Eplerenone; Fibr

2002
Corticosteroid receptors, 11 beta-hydroxysteroid dehydrogenase, and the heart.
    Vitamins and hormones, 2003, Volume: 66

    Topics: 11-beta-Hydroxysteroid Dehydrogenases; Adrenal Cortex Hormones; Aldosterone; Animals; Binding Sites;

2003
Neurohormones and heart failure: the importance of aldosterone.
    International journal of clinical practice, 2006, Volume: 60, Issue:7

    Topics: Adaptation, Physiological; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert

2006
[Aldosterone].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Apr-28, Volume: 65 Suppl 4

    Topics: Aldosterone; Cardiomegaly; Heart Failure; Humans; Myocardium

2007
Pathophysiology of hypertension and ischemic heart disease.
    International anesthesiology clinics, 1980,Winter, Volume: 18, Issue:4

    Topics: Adult; Aldosterone; Animals; Cardiomegaly; Coronary Circulation; Coronary Disease; Endocardium; Hear

1980
The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy.
    The American journal of cardiology, 1995, Nov-02, Volume: 76, Issue:13

    Topics: Adaptation, Physiological; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; An

1995
Role of neurohormones in ventricular adaptation and failure.
    The American journal of cardiology, 1994, Apr-07, Volume: 73, Issue:10

    Topics: Adaptation, Physiological; Aldosterone; Angiotensin II; Animals; Cardiomegaly; Disease Models, Anima

1994
Aldosterone and heart failure.
    European heart journal, 1995, Volume: 16 Suppl N

    Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomegaly; Endomyocardial Fibrosi

1995
Mineralocorticoids, salt, hypertension: effects on the heart.
    Steroids, 1996, Volume: 61, Issue:4

    Topics: Aldosterone; Animals; Cardiomegaly; Fibrosis; Heart; Humans; Hypertension; Hypokalemia; Mineralocort

1996
Aldosterone action: fact, failure and the future.
    Clinical and experimental pharmacology & physiology. Supplement, 1998, Volume: 25

    Topics: 11-beta-Hydroxysteroid Dehydrogenases; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Forecasti

1998
Cellular calcium and magnesium metabolism in the pathophysiology and treatment of hypertension and related metabolic disorders.
    The American journal of medicine, 1992, Aug-31, Volume: 93, Issue:2A

    Topics: Aldosterone; Blood Glucose; Blood Pressure; Calcium; Calcium Channel Blockers; Cardiomegaly; Diabete

1992
Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.
    Circulation, 1991, Volume: 83, Issue:6

    Topics: Aldosterone; Animals; Cardiomegaly; Fibrosis; Humans; Hypertension; Models, Cardiovascular; Myocardi

1991

Trials

5 trials available for aldosterone and Cardiac Hypertrophy

ArticleYear
A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease.
    Journal of veterinary internal medicine, 2018, Volume: 32, Issue:5

    Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pr

2018
Heart failure with preserved ejection fraction in children: hormonal imbalance between aldosterone and brain natriuretic peptide.
    Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:9

    Topics: Adolescent; Adult; Age Factors; Aldosterone; Cardiomegaly; Child; Child, Preschool; Disease-Free Sur

2013
The relation between cardiac hypertrophy and hypertension.
    Acta medica Scandinavica. Supplementum, 1983, Volume: 672

    Topics: Aldosterone; Blood Glucose; Blood Pressure; Cardiomegaly; Heart Ventricles; Humans; Hypertension; In

1983
Effects of sustained-release nicardipine on regression of left ventricular hypertrophy in systemic hypertension.
    The American journal of cardiology, 1992, Jun-15, Volume: 69, Issue:19

    Topics: Aldosterone; Blood Pressure; Cardiomegaly; Delayed-Action Preparations; Double-Blind Method; Echocar

1992
Effects of captopril and minoxidil on left ventricular hypertrophy in resistant hypertensive patients: a 6 month double-blind comparison.
    Journal of the American College of Cardiology, 1990, Volume: 16, Issue:1

    Topics: Adult; Aged; Aldosterone; Captopril; Cardiomegaly; Double-Blind Method; Echocardiography; Humans; Hy

1990

Other Studies

113 other studies available for aldosterone and Cardiac Hypertrophy

ArticleYear
Clinical Characteristics of Target Organ Damage in Primary Aldosteronism with or without Metabolic Syndrome.
    Journal of diabetes research, 2022, Volume: 2022

    Topics: Albuminuria; Aldosterone; Cardiomegaly; Carotid Intima-Media Thickness; Glucose; Humans; Hyperaldost

2022
BST-1 aggravates aldosterone-induced cardiac hypertrophy via the Ca2+ /CaN/NFATc3 pathway.
    General physiology and biophysics, 2023, Volume: 42, Issue:4

    Topics: ADP-ribosyl Cyclase 1; Aldosterone; Animals; Calcium; Cardiomegaly; Cyclic ADP-Ribose; NFATC Transcr

2023
Differential Role of Aldosterone and Transforming Growth Factor Beta-1 in Cardiac Remodeling.
    International journal of molecular sciences, 2023, Jul-31, Volume: 24, Issue:15

    Topics: Aldosterone; Animals; Cardiomegaly; Eplerenone; Fibrosis; Male; Mice; Mice, Transgenic; Myocytes, Ca

2023
Cyclovirobuxine D alleviates aldosterone-induced myocardial hypertrophy by protecting mitochondrial function depending on the mutual regulation of Nrf2-SIRT3.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 167

    Topics: Aldosterone; Cardiomegaly; Humans; Mitochondria; Molecular Docking Simulation; NF-E2-Related Factor

2023
TRIF/miR-34a mediates aldosterone-induced cardiac inflammation and remodeling.
    Clinical science (London, England : 1979), 2020, 06-26, Volume: 134, Issue:12

    Topics: Adaptor Proteins, Vesicular Transport; Aldosterone; Animals; Animals, Newborn; Cardiomegaly; Fibrosi

2020
Genetic Ablation of Fgf23 or Klotho Does not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload.
    Scientific reports, 2017, 09-12, Volume: 7, Issue:1

    Topics: Aldosterone; Animals; Biomarkers; Blood Pressure; Cardiomegaly; Disease Models, Animal; Disease Susc

2017
IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis.
    Cardiovascular research, 2018, 04-01, Volume: 114, Issue:5

    Topics: Adult; Aldosterone; Animals; Cardiomegaly; Case-Control Studies; Cells, Cultured; Collagen; Cytokine

2018
Diuretic herb Gomphrena celosioides Mart. (Amaranthaceae) promotes sustained arterial pressure reduction and protection from cardiac remodeling on rats with renovascular hypertension.
    Journal of ethnopharmacology, 2018, Oct-05, Volume: 224

    Topics: Aldosterone; Amaranthaceae; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Diuretic

2018
MicroRNA-21 ablation exacerbates aldosterone-mediated cardiac injury, remodeling, and dysfunction.
    American journal of physiology. Endocrinology and metabolism, 2018, 12-01, Volume: 315, Issue:6

    Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Hyperaldosteronism; Male; Mice; Mice, Knockout;

2018
Dendritic cells are crucial for cardiovascular remodeling and modulate neutrophil gelatinase-associated lipocalin expression upon mineralocorticoid receptor activation.
    Journal of hypertension, 2019, Volume: 37, Issue:7

    Topics: Aldosterone; Animals; Cardiomegaly; Cardiovascular System; CD11 Antigens; Coculture Techniques; Dend

2019
The ANF-RGC gene motif (669)WTAPELL(675) is vital for blood pressure regulation: biochemical mechanism.
    Biochemistry, 2013, Apr-02, Volume: 52, Issue:13

    Topics: Aldosterone; Amino Acid Motifs; Animals; Blood Pressure; Calcium; Cardiomegaly; Catalytic Domain; Ch

2013
Blood pressure variability activates cardiac mineralocorticoid receptor and induces cardiac remodeling in hypertensive rats.
    Circulation journal : official journal of the Japanese Circulation Society, 2013, Volume: 77, Issue:6

    Topics: Active Transport, Cell Nucleus; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cell Nucleus; Ep

2013
High-salt intake induces cardiomyocyte hypertrophy in rats in response to local angiotensin II type 1 receptor activation.
    The Journal of nutrition, 2014, Volume: 144, Issue:10

    Topics: Acetylcysteine; Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Body

2014
Attenuation of renovascular hypertension by cyclooxygenase-2 inhibitor partly through ANP release.
    Peptides, 2015, Volume: 69

    Topics: Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Cyclo

2015
TRAF3IP2 mediates aldosterone/salt-induced cardiac hypertrophy and fibrosis.
    Molecular and cellular endocrinology, 2016, 07-05, Volume: 429

    Topics: Adaptor Proteins, Signal Transducing; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cell Adhes

2016
Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone+salt-induced cardiac fibrosis in vivo.
    Journal of molecular and cellular cardiology, 2016, Volume: 98

    Topics: Adaptor Proteins, Signal Transducing; Aldosterone; AMP-Activated Protein Kinases; Animals; Cardiomeg

2016
Effects of early aldosterone antagonism on cardiac remodeling in rats with aortic stenosis-induced pressure overload.
    International journal of cardiology, 2016, Nov-01, Volume: 222

    Topics: Aldosterone; Animals; Aortic Valve Stenosis; Cardiomegaly; Electrocardiography; Male; Mineralocortic

2016
A novel aldosterone synthase inhibitor ameliorates mortality in pressure-overload mice with heart failure.
    European journal of pharmacology, 2017, Jan-15, Volume: 795

    Topics: Aldosterone; Animals; Cardiomegaly; Cytochrome P-450 CYP11B2; Cytochrome P-450 Enzyme Inhibitors; He

2017
Aldosterone induces cardiotrophin-1 expression in HL-1 adult cardiomyocytes.
    Endocrinology, 2008, Volume: 149, Issue:10

    Topics: Age Factors; Aldosterone; Animals; Cardiomegaly; Cell Line; Cytokines; Dose-Response Relationship, D

2008
Relations of biomarkers representing distinct biological pathways to left ventricular geometry.
    Circulation, 2008, Nov-25, Volume: 118, Issue:22

    Topics: Aldosterone; Biomarkers; C-Reactive Protein; Cardiomegaly; Electrocardiography; Female; Fibrin; Hear

2008
Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2009, Volume: 32, Issue:7

    Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Vess

2009
Chronic intermittent hypoxia induces 11beta-hydroxysteroid dehydrogenase in rat heart.
    Endocrinology, 2009, Volume: 150, Issue:9

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosteron

2009
Growth arrest specific protein 6 participates in DOCA-induced target-organ damage.
    Hypertension (Dallas, Tex. : 1979), 2009, Volume: 54, Issue:2

    Topics: Acute Kidney Injury; Albuminuria; Aldosterone; Analysis of Variance; Animals; Blood Pressure; Cardio

2009
miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy.
    Proceedings of the National Academy of Sciences of the United States of America, 2009, Jul-21, Volume: 106, Issue:29

    Topics: Aldosterone; Animals; Base Sequence; Calcineurin; Cardiomegaly; Cell Line; Disease Models, Animal; G

2009
Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism.
    American journal of physiology. Heart and circulatory physiology, 2009, Volume: 297, Issue:5

    Topics: Administration, Oral; Aldosterone; Animals; Cardiomegaly; Collagen Type I; Cytochrome P-450 CYP1A1;

2009
Fetal adrenal gland alterations in a rat model of adverse intrauterine environment.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2010, Volume: 298, Issue:4

    Topics: Adrenal Glands; Aldosterone; Animals; Cardiomegaly; Corticosterone; Disease Models, Animal; DNA Prim

2010
Caveolin-1 ablation reduces the adverse cardiovascular effects of N-omega-nitro-L-arginine methyl ester and angiotensin II.
    Endocrinology, 2010, Volume: 151, Issue:3

    Topics: Aldosterone; Amino Acid Sequence; Angiotensin II; Animals; Blood Pressure; Cardiomegaly; Caveolin 1;

2010
miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy.
    The Journal of biological chemistry, 2010, Apr-16, Volume: 285, Issue:16

    Topics: Aldosterone; Animals; Base Sequence; Cardiomegaly; Gene Expression; Humans; In Vitro Techniques; Iso

2010
[Inhibitory effect on activated renin-angiotensin system by astragaloside IV in rats with pressure-overload induced cardiac hypertrophy].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2009, Volume: 34, Issue:24

    Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomegaly; Enzyme-Linked Immunosorbent Assa

2009
Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone.
    Clinical and experimental pharmacology & physiology, 2010, Volume: 37, Issue:9

    Topics: Aldosterone; Angiotensin II; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Car

2010
Aldosterone inhibition and cardiovascular protection: more important than it once appeared.
    Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:4

    Topics: Aldosterone; Atherosclerosis; Blood Vessels; Cardiomegaly; Cardiotonic Agents; Endothelium; Heart Fa

2010
Cardiac hypertrophy, low blood pressure, and low aldosterone levels in mice devoid of the three circadian PAR bZip transcription factors DBP, HLF, and TEF.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2010, Volume: 299, Issue:4

    Topics: Adrenergic beta-Antagonists; Aldosterone; Animals; Atenolol; Basic-Leucine Zipper Transcription Fact

2010
Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice.
    The Journal of clinical investigation, 2010, Volume: 120, Issue:9

    Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Fibrosis; Heart; Hypert

2010
Salt-induced cardiac hypertrophy and interstitial fibrosis are due to a blood pressure-independent mechanism in Wistar rats.
    The Journal of nutrition, 2010, Volume: 140, Issue:10

    Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agen

2010
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
    Clinical and experimental pharmacology & physiology, 2010, Volume: 37, Issue:12

    Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme

2010
T-type Ca²+ signalling regulates aldosterone-induced CREB activation and cell death through PP2A activation in neonatal cardiomyocytes.
    Cardiovascular research, 2011, Apr-01, Volume: 90, Issue:1

    Topics: Aldosterone; Animals; Animals, Newborn; Apoptosis; bcl-X Protein; Calcium Channels, T-Type; Calcium

2011
New take on the role of angiotensin II in cardiac hypertrophy and fibrosis.
    Hypertension (Dallas, Tex. : 1979), 2011, Volume: 57, Issue:6

    Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Fibrosis; Humans; Hypertension; Inflammation; Mi

2011
In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy.
    Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:2

    Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Collagen; D

2012
Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1.
    Experimental physiology, 2012, Volume: 97, Issue:6

    Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Fibrosis; Heart; Immediate-Early Proteins; Infla

2012
Unilateral primary aldosteronism with spontaneous remission after long-term spironolactone therapy.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:4

    Topics: Adrenal Gland Neoplasms; Adult; Aldosterone; Antihypertensive Agents; Cardiomegaly; Enalapril; Human

2012
Effects of proangiotensin-12 infused continuously over 14 days in conscious rats.
    European journal of pharmacology, 2012, May-15, Volume: 683, Issue:1-3

    Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme

2012
Aldosterone inhibits the fetal program and increases hypertrophy in the heart of hypertensive mice.
    PloS one, 2012, Volume: 7, Issue:5

    Topics: Aldosterone; Animals; Cardiomegaly; Cyclic AMP Response Element-Binding Protein; Female; Fetus; Gene

2012
[Hypertension-induced fibrosis: a balance story].
    Annales de cardiologie et d'angeiologie, 2012, Volume: 61, Issue:3

    Topics: Aldosterone; Angiotensin II; Animals; Bone Morphogenetic Proteins; Cardiomegaly; Disease Models, Ani

2012
Antihypertrophic effects of combined inhibition of the renin-angiotensin system (RAS) and neutral endopeptidase (NEP) in progressive, tachycardia-induced experimental heart failure.
    Naunyn-Schmiedeberg's archives of pharmacology, 2012, Volume: 385, Issue:11

    Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomegaly; Cardiovascular Agents;

2012
An autopsy case of bilateral adrenal pheochromocytoma-associated cerebral hemorrhage.
    Legal medicine (Tokyo, Japan), 2013, Volume: 15, Issue:2

    Topics: Adrenal Gland Neoplasms; Adrenocorticotropic Hormone; Adult; Aldosterone; Arteries; Arteriosclerosis

2013
Aldosterone augments endothelin-1-induced cardiac myocyte hypertrophy with the reinforcement of the JNK pathway.
    FEBS letters, 2002, Jul-31, Volume: 524, Issue:1-3

    Topics: Aldosterone; Animals; Animals, Newborn; Cardiomegaly; Cells, Cultured; Endothelin-1; Enzyme Activati

2002
Endothelin ETA receptor antagonism does not attenuate angiotensin II-induced cardiac hypertrophy in vivo in rats.
    Clinical and experimental pharmacology & physiology, 2003, Volume: 30, Issue:4

    Topics: Aldosterone; Angiotensin II; Animals; Arginine Vasopressin; Blood Pressure; Cardiomegaly; Endothelin

2003
Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure.
    Circulation research, 2003, Jul-11, Volume: 93, Issue:1

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Dis

2003
[Adrenal cortex hormone (Cortigarant) in heart therapy].
    Munchener medizinische Wochenschrift (1950), 1962, Sep-21, Volume: 104

    Topics: Adrenal Cortex; Adrenal Cortex Hormones; Aldosterone; Cardiomegaly; Diuretics

1962
Aldosterone increases NHE-1 expression and induces NHE-1-dependent hypertrophy in neonatal rat ventricular myocytes.
    Hypertension (Dallas, Tex. : 1979), 2003, Volume: 42, Issue:6

    Topics: Aldosterone; Animals; Animals, Newborn; Cardiomegaly; Cell Size; Cells, Cultured; Enzyme Inhibitors;

2003
Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart.
    The Journal of laboratory and clinical medicine, 2004, Volume: 143, Issue:1

    Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen Type I; Disease Models, Animal; Drug Th

2004
Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats.
    Journal of hypertension, 2004, Volume: 22, Issue:5

    Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; B

2004
Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy.
    Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:6

    Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Blood Pressure; Cardiomegaly; Cell Size; Eplerenone

2004
Vascular synthesis of aldosterone: role in hypertension.
    Molecular and cellular endocrinology, 2004, Mar-31, Volume: 217, Issue:1-2

    Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Vessels; Cardi

2004
Synchronization and integration of multiple hypertrophic pathways in the heart.
    Cardiovascular research, 2004, Aug-15, Volume: 63, Issue:3

    Topics: Aldosterone; Cardiomegaly; Cytokines; Humans; Integrins; Myocardium; Myocytes, Cardiac; Renin-Angiot

2004
Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat.
    Circulation, 2005, Jan-04, Volume: 111, Issue:1

    Topics: Aldosterone; Angiotensin II; Animals; Atrial Fibrillation; Atrial Natriuretic Factor; Cardiac Pacing

2005
Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
    European journal of pharmacology, 2005, Sep-20, Volume: 519, Issue:3

    Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blood Glu

2005
Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2005, Volume: 28, Issue:5

    Topics: Acetylcysteine; Aldosterone; Animals; Blood Pressure; Cardiomegaly; Chemokine CCL2; Echocardiography

2005
Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
    Hypertension (Dallas, Tex. : 1979), 2006, Volume: 47, Issue:4

    Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiomegaly; Cardiotonic Agents; Coronary Vessels; Corti

2006
Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone.
    Hypertension (Dallas, Tex. : 1979), 2006, Volume: 47, Issue:4

    Topics: Aldosterone; Animals; Cardiac Output, Low; Cardiomegaly; Cardiotonic Agents; Corticosterone; Epleren

2006
Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1.
    Cardiovascular research, 2006, Jun-01, Volume: 70, Issue:3

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adrenal Cortex Hormones; Adrenergic Agents; Aldosterone

2006
Effect of parathyroidectomy on cardiac fibrosis and apoptosis: possible role of aldosterone.
    Nephron. Physiology, 2006, Volume: 103, Issue:3

    Topics: Aldosterone; Animals; Apoptosis; Cardiomegaly; Fibrosis; Heart; Hypoparathyroidism; Male; Myocardium

2006
Estrogen and salt sensitivity in the female mRen(2). Lewis rat.
    American journal of physiology. Regulatory, integrative and comparative physiology, 2006, Volume: 291, Issue:5

    Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiomegaly; Estrogens; Female; Gene Expressi

2006
Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice.
    Clinical and experimental pharmacology & physiology, 2006, Volume: 33, Issue:9

    Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Eplerenone; Heart; Hy

2006
Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats.
    Hypertension (Dallas, Tex. : 1979), 2006, Volume: 48, Issue:5

    Topics: Aldosterone; Androstenes; Animals; Cardiomegaly; Cardiovascular System; Collagen; Estradiol; Estroge

2006
Effects of eplerenone and salt intake on left ventricular remodeling after myocardial infarction in rats.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2006, Volume: 29, Issue:8

    Topics: Aldosterone; Animals; Cardiomegaly; Diet, Sodium-Restricted; Echocardiography; Eplerenone; Fibrosis;

2006
Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
    American journal of hypertension, 2007, Volume: 20, Issue:10

    Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensinog

2007
Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse.
    Hypertension (Dallas, Tex. : 1979), 2007, Volume: 50, Issue:5

    Topics: Aldosterone; Angiotensin II; Animals; Atherosclerosis; Blood Pressure; Cardiomegaly; Diet, Atherogen

2007
Aldosterone-and-salt-induced cardiac fibrosis is independent from angiotensin II type 1a receptor signaling in mice.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2007, Volume: 30, Issue:10

    Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Blotting, Western; Ca

2007
(Pro)renin receptor peptide inhibitor "handle-region" peptide does not affect hypertensive nephrosclerosis in Goldblatt rats.
    Hypertension (Dallas, Tex. : 1979), 2008, Volume: 51, Issue:3

    Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Disease Models, Animal; Hypertension, Renovascul

2008
RNAi inhibition of mineralocorticoid receptors prevents the development of cold-induced hypertension.
    American journal of physiology. Heart and circulatory physiology, 2008, Volume: 294, Issue:4

    Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Cardiomegaly; Cold Temperature; Dependovirus; Dis

2008
Effect of the new calcium antagonist (+/-)-(R*)-3-[(R*)-1-benzyl-3- piperidyl] methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5- pyridinedicarboxylate hydrochloride (KW-3049) on cardiac hypertrophy in spontaneously hypertensive rats.
    The Journal of toxicological sciences, 1993, Volume: 18 Suppl 3

    Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiomegal

1993
[Possible influence of hemodynamic and neurohormonal factors on the heart's response to arterial hypertension].
    Cardiologia (Rome, Italy), 1994, Volume: 39, Issue:4

    Topics: Adult; Aldosterone; Cardiomegaly; Female; Heart; Hemodynamics; Humans; Hypertension; Linear Models;

1994
High glucose stimulates aldosterone-induced hypertrophy via type I mineralocorticoid receptors in neonatal rat cardiomyocytes.
    Endocrinology, 1996, Volume: 137, Issue:10

    Topics: Aldosterone; Animals; Animals, Newborn; Cardiomegaly; Cell Division; Cells, Cultured; Extracellular

1996
The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis.
    The American journal of physiology, 1996, Volume: 271, Issue:5 Pt 1

    Topics: Aldosterone; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Body Weight; Canr

1996
Hypertensive cardiomegaly caused by an aldosterone-secreting adenoma in a newborn.
    Journal of endocrinological investigation, 1997, Volume: 20, Issue:2

    Topics: Adenoma; Adrenalectomy; Aldosterone; Cardiomegaly; Humans; Hyperaldosteronism; Hypertension; Infant;

1997
[Association between blood pressure and circulating hormonal factors with left ventricular mass in patients with essential hypertension older than 55 years of age].
    Medicina clinica, 1997, Oct-11, Volume: 109, Issue:12

    Topics: Aged; Aldosterone; Cardiomegaly; Endothelin-1; Epinephrine; Female; Humans; Hypertension; Male; Midd

1997
Vascular smooth muscle cell polyploidy and cardiomyocyte hypertrophy due to chronic NOS inhibition in vivo.
    The American journal of physiology, 1998, Volume: 274, Issue:1

    Topics: Actins; Aldosterone; Animals; Aorta, Thoracic; Carbachol; Cardiomegaly; Cell Cycle; DNA; Heart; Hype

1998
Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis.
    Circulation, 1999, May-25, Volume: 99, Issue:20

    Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrial Natriuretic Factor; C

1999
Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy.
    Endocrinology, 2000, Volume: 141, Issue:5

    Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Cytochrome P-450 CYP11B2; Heart; Male; Myocardiu

2000
Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
    Journal of hypertension, 2000, Volume: 18, Issue:6

    Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Cardiomeg

2000
Cardiac aldosterone production in genetically hypertensive rats.
    Hypertension (Dallas, Tex. : 1979), 2000, Volume: 36, Issue:4

    Topics: Adrenalectomy; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardi

2000
Aldosterone and myocardial infarction--are aldosterone antagonists needed to prevent remodelling or does ACE inhibition suffice?
    Cardiovascular drugs and therapy, 2001, Volume: 15, Issue:4

    Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Canrenoic Acid; Captopril; Cardiomegaly; Huma

2001
Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy.
    Circulation, 2002, Feb-12, Volume: 105, Issue:6

    Topics: Aldosterone; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Natriuretic Factor; Bo

2002
Effects of losartan and benazepril on abnormal circadian blood pressure rhythm and target organ damage in SHRSP.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2002, Volume: 24, Issue:3

    Topics: Aldosterone; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cardiomegaly; Circadian

2002
Effects of long-term enalapril and losartan therapy of heart failure on cardiovascular aldosterone.
    Journal of endocrinological investigation, 2002, Volume: 25, Issue:5

    Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output, Low;

2002
Cardiomyopathy in an adult with Bartter's syndrome and hypokalemia. Hemodynamic, angiographic and metabolic studies.
    The American journal of cardiology, 1977, Volume: 40, Issue:6

    Topics: Adult; Aldosterone; Bartter Syndrome; Cardiomegaly; Cardiomyopathies; Child; Female; Hemodynamics; H

1977
Hypertension, hypokalemia, hyporeninemia and severe target organ damage.
    Canadian Medical Association journal, 1976, Feb-07, Volume: 114, Issue:3

    Topics: Aldosterone; Blood Pressure; Cardiomegaly; Female; Humans; Hyperaldosteronism; Hypertension; Hypokal

1976
[Comparative study of plasma levels of renin and aldosterone activity in essential arterial hypertension in relation to duration of the disease and the presence of complications].
    Bollettino della Societa italiana di cardiologia, 1977, Volume: 22, Issue:8

    Topics: Acute Disease; Adolescent; Adult; Aldosterone; Cardiomegaly; Chronic Disease; Female; Humans; Hypert

1977
Effect of manidipine on cardiac hypertrophy and coronary circulation in DOCA/salt hypertensive rats.
    Blood pressure. Supplement, 1992, Volume: 3

    Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Coronary Circulation; C

1992
Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin.
    Journal of human hypertension, 1992, Volume: 6, Issue:1

    Topics: Adrenergic alpha-Antagonists; Adult; Aldosterone; Antihypertensive Agents; Blood Pressure; Cardiomeg

1992
Effect of a reduction in sodium intake on cold-induced elevation of blood pressure in the rat.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1992, Volume: 200, Issue:4

    Topics: Acclimatization; Aldosterone; Animals; Blood Pressure; Body Weight; Cardiomegaly; Cold Temperature;

1992
Reactive and reparative myocardial fibrosis in arterial hypertension in the rat.
    Cardiovascular research, 1992, Volume: 26, Issue:7

    Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen; Disease Models, Animal; Fibrosis; Hype

1992
Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.
    The Journal of laboratory and clinical medicine, 1992, Volume: 120, Issue:6

    Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Collagen; Desoxycorticosterone; Endomyocardial F

1992
Remodeling of the rat right and left ventricles in experimental hypertension.
    Circulation research, 1990, Volume: 67, Issue:6

    Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen; Fibrosis; Heart Ventricles; Hemodynami

1990
Influence of the arterial blood pressure and nonhemodynamic factors on left ventricular hypertrophy in moderate essential hypertension.
    The American journal of cardiology, 1991, Oct-01, Volume: 68, Issue:9

    Topics: Adult; Aldosterone; Blood Pressure; Blood Pressure Determination; Cardiomegaly; Epinephrine; Female;

1991
Effect of benazepril hydrochloride on cardiac hypertrophy in spontaneously hypertensive rats.
    Arzneimittel-Forschung, 1991, Volume: 41, Issue:6

    Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Biomarkers; Blood Pres

1991
Therapeutic response may be predicted by some clinical parameters in essential hypertensive patients.
    Journal of human hypertension, 1991, Volume: 5, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Antihypertensive Agents; Blood Pressure; Cardiomegaly;

1991
Relationship between parathyroid hormone and left ventricular mass in moderate essential hypertension.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1991, Volume: 9, Issue:6

    Topics: Aldosterone; Blood Pressure; Cardiomegaly; Epinephrine; Female; Humans; Hypertension; Male; Middle A

1991
Alterations in dietary sodium affect isoproterenol-induced cardiac hypertrophy.
    Journal of molecular and cellular cardiology, 1990, Volume: 22, Issue:10

    Topics: Aldosterone; Animals; Body Water; Cardiomegaly; Diet, Sodium-Restricted; Isoproterenol; Male; Organ

1990
Modulation of left ventricular hypertrophy by dietary salt and inhibition of angiotensin converting enzyme.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1988, Volume: 6, Issue:4

    Topics: Aldosterone; Animals; Body Weight; Cardiomegaly; Enalapril; Hypertension; Lisinopril; Peptidyl-Dipep

1988
[Effects of diltiazem on developing blood pressure and accompanying cardiac and vascular hypertrophy in SHR].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1985, Volume: 86, Issue:3

    Topics: Aldosterone; Animals; Aorta; Aortic Diseases; Benzazepines; Cardiomegaly; Diltiazem; Hindlimb; Hyper

1985
Isomyosin transitions in ventricles of aldosterone-salt hypertensive rats.
    Hypertension (Dallas, Tex. : 1979), 1986, Volume: 8, Issue:2

    Topics: Aldosterone; Animals; Blood Pressure; Body Weight; Cardiomegaly; Electrophoresis, Polyacrylamide Gel

1986
Left ventricular structural characteristics in unilateral renovascular hypertension and primary aldosteronism.
    The American journal of cardiology, 1988, Dec-01, Volume: 62, Issue:17

    Topics: Adult; Aldosterone; Blood Pressure; Blood Volume; Cardiomegaly; Echocardiography; Female; Humans; Hy

1988
Does the renin-angiotensin-aldosterone system modify cardiac structure and function in essential hypertension?
    The American journal of medicine, 1988, Mar-11, Volume: 84, Issue:3A

    Topics: Aldosterone; Cardiomegaly; Female; Humans; Hypertension; Male; Myocardium; Renin-Angiotensin System;

1988
Regression of electrocardiographic left ventricular hypertrophy following treatment of primary hyperaldosteronism.
    Journal of human hypertension, 1988, Volume: 2, Issue:3

    Topics: Adult; Aldosterone; Blood Pressure; Cardiomegaly; Electrocardiography; Humans; Hyperaldosteronism; M

1988
Long-term antihypertensive treatment may induce normalization of left ventricular mass before complete regression of vascular structural changes: consequences for cardiac function at rest and during stress.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 1988, Volume: 6, Issue:4

    Topics: Adult; Aldosterone; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Catecholamines; Drug Admi

1988
Cardiac function and cardiovascular hormone balance during hemodialysis with special reference to atrial natriuretic peptide.
    Clinical nephrology, 1988, Volume: 30, Issue:6

    Topics: Adult; Aged; Aldosterone; Atrial Natriuretic Factor; Cardiomegaly; Echocardiography; Female; Heart;

1988
Prevalence and clinical peculiarities of essential hypertension in a population living at high altitude.
    Cor et vasa, 1985, Volume: 27, Issue:1

    Topics: Adult; Age Factors; Aldosterone; Alkalosis, Respiratory; Altitude; Altitude Sickness; Cardiomegaly;

1985
Participation of endogenous catecholamines in the regulation of left ventricular mass in progeny of hypertensive parents.
    Circulation, 1985, Volume: 72, Issue:1

    Topics: Adolescent; Adult; Aldosterone; Atenolol; Blood Pressure; Blood Volume; Body Weight; Cardiomegaly; C

1985
Co-existing aldosterone-producing adrenal tumor (aldosteronoma) and bilateral renovascular lesions.
    The Journal of urology, 1969, Volume: 101, Issue:1

    Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Aldosterone; Angiography; Blood Pressure; Carbon Di

1969
Essential hypertension: renin and aldosterone, heart attack and stroke.
    The New England journal of medicine, 1972, Mar-02, Volume: 286, Issue:9

    Topics: Adult; Aldosterone; Cardiomegaly; Cerebrovascular Disorders; Female; Humans; Hypertension; Male; Mid

1972
[Renin activity in the blood plasma in pheochromocytoma].
    Kardiologiia, 1973, Volume: 13, Issue:4

    Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aldosterone; Cardiomegaly; Catecholamines; Chromatograph

1973